Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mario Castro, Klaus F. Rabe, Jonathan Corren, Ian D. Pavord, Constance H. Katelaris, Yuji Tohda, Bingzhi Zhang, Megan S. Rice, Jaman Maroni, Paul Rowe, Gianluca Pirozzi, Nikhil Amin, Marcella Ruddy, Bolanle Akinlade, Neil M.H. Graham, Ariel Teper. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 604s Year: 2005 Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Short-term effects of pulmonary rehabilitation on asthma control in patients with moderate-severe unstable asthma Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Severe exacerbations predict excess lung function decline in asthma Source: Eur Respir J 2007; 30: 452-456 Year: 2007 How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy? Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002 Regarding the role of FENO in predicting failure after ICS reduction in mild-to-moderate asthma patients Source: Eur Respir J, 56 (2) 2002375; 10.1183/13993003.02375-2020 Year: 2020 Budesonide/formoterol in a single inhaler rapidly improves lung function in adult patients with mild or moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002 Assessing small airway impairment in mild-to-moderate smoking asthmatic patients Source: Eur Respir J 2016; 47: 1264-1267 Year: 2016